Home / Themes / MedTech Short '25: Heavy China Exposure
MedTech Short '25: Heavy China Exposure
Last updated
Theme thesis · 3/5 sections · Tickers 2 with notes · 9 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsEven though the BIOSECURE Act did not pass in April, the Trump 2.0 administration has signaled ongoing hostility toward China-linked biopharma operations. De fa
Thesis
Even though the BIOSECURE Act did not pass in April, the Trump 2.0 administration has signaled ongoing hostility toward China-linked biopharma operations. De facto pressure is being exerted through executive actions, federal agency contract constraints, and rhetorical/political overhangs. That's already driving anticipatory behavior—such as supply chain restructuring, domestic capex shifts, and RFP rerouting—hurting multinationals with large China exposure.
Bull case
Policy Pressure Despite Legislative Delay: Even without passage, agencies are quietly shifting procurement preferences away from companies with Chinese dependencies. Sentiment remains highly negative for bio multinationals.
Early Capex Shifts & Contract Losses: Anecdotal reports from smaller domestic players (TKNO, NOTV) indicate new client wins and RFP redirection from China-exposed competitors like DHR, IQV even in the absence of a formal mandate
China Still a Fundamental Drag: China remains a weak spot in life science earnings reports (e.g., WAT, DHR), as sentiment, pricing pressure, and trade disruptions persist amid broader U.S.-China decoupling dynamics
Bear case
BIOSECURE Act Failure Buys Time: With the act failing to pass, companies like DHR, IQV, and TECH get breathing room to adapt operations, lobby for exemptions, and avoid abrupt revenue loss or contract restrictions.
Stimulus & Stabilization in China and EU: Signs of stabilization in Chinese demand and fresh EU health system stimulus (including for diagnostics and biologics) could support revenue rebounds for multinationals with deep overseas exposure.
U.S. Cost Inflation & Supply Chain Complexity: Over-rotation into U.S.-only manufacturing could expose domestic players to capacity constraints and margin pressure, potentially making global, diversified firms like AMGN or NVO more competitive on cost and innovation.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| Company-Specific China Revenue and Commentary | Quarterly | Reveals demand softness, FX headwinds, and structural erosion in China exposure. | Google_Sheets |
| CRO/CDMO RFP Shifts from China to U.S. Providers | Quarterly | Measures dealflow and outsourcing shifts; a pivot away from IQV/DHR favors the short thesis. | Google_Sheets |
| Biopharma & Medtech Export Volume to U.S. (China & EU) | Monthly | Tracks trade rerouting and pressure from onshoring; falling volumes confirm thesis. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| AMGN_a4f12076 | 2026 will be a year of disciplined data generation. From a number of exciting phase II and phase III programs that will pave the way for long-term growth at Amgen Inc. | 2026-01-01 | 2026-12-31 | Data generation and potential readouts from multiple ongoing Phase III clinical trials for Meritide in chronic weight management, ASCVD, heart failure, and sleep apnea. | Positive data from these late-stage trials could significantly enhance Amgen's competitive position in the rapidly expanding obesity and cardiometabolic markets, materially impacting future revenue guidance and valuation. Conversely, unfavorable outcomes would represent a significant setback. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_f22b3322 | As the study matures, we will update on the date for primary analysis as appropriate. | 2026-04-24 | 2026-12-31 | Update on the date for primary analysis of the fully enrolled OCEAN A outcome study for opaziran, an siRNA medicine targeting Lp(a) to reduce cardiovascular risk. | This update will establish the timeline for pivotal data availability for a potential best-in-class therapy in cardiovascular disease, influencing investor sentiment and future valuation. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_c80d6f15 | we expect to initiate two pivotal studies this year. | 2026-01-01 | 2026-12-31 | Initiation of two pivotal (Phase III) studies for Amgen's B cell depletion therapy in autoimmune hepatitis and chronic inflammatory demyelinating polyneuropathy (CIDP). | These initiations signify the advancement of new potential indications for Amgen's rare disease portfolio, expanding its market opportunity and future revenue streams. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_fe4d51bf | We will update you on those discussions as necessary. | 2026-04-24 | 2026-12-31 | Resolution of ongoing discussions with the FDA regarding TABNIO's (avacopan) following a voluntary withdrawal request related to primary endpoint result readjudication. | The outcome will determine the future commercial viability of TABNIO's, impacting Amgen's rare disease portfolio and potentially leading to a re-evaluation of the product's sales trajectory. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_f1821dd7 | We plan to launch TEPEZZA in additional markets in 2026 | 2026-01-01 | 2026-12-31 | Launch of TEPEZZA in additional international markets. | Expanding TEPEZZA's geographic reach will contribute to its global sales growth and further establish Amgen's presence in the thyroid eye disease market. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_ce3d8cd2 | Including preparing for Miratide's launch. | 2026-01-01 | 2026-12-31 | Preparations and potential launch of Meritide, a novel therapy for obesity, type 2 diabetes, and related conditions. | Meritide is a key growth driver for Amgen. Its successful launch and market penetration would significantly impact Amgen's revenue and competitive position in the rapidly growing GLP-1 market. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| ABBV_ac706a0a | US submission is planned for the second quarter | 2026-04-01 | 2026-06-30 | US regulatory submission for RINVOQ in alopecia areata. | This is a critical step towards potential US market entry for RINVOQ in alopecia areata, a significant dermatological condition. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_171a2b75 | Over the course of 2026 | 2026-04-26 | 2026-12-31 | Readout of Phase 3 data for both RINVOQ and lutekizumab in hidradenitis suppurativa. | Positive data could lead to new indications for RINVOQ and establish lutekizumab as a lead asset, significantly expanding AbbVie's immunology franchise. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_1bed7b86 | This year | 2026-04-26 | 2026-12-31 | Data from the Crohn's disease platform study evaluating SKYRIZI in combination with ABBV 3A2 and lutekizumab. | This data could demonstrate superior efficacy for patients, strengthening SKYRIZI's position and AbbVie's overall IBD portfolio, especially for patients who have already received SKYRIZI. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_dfdda14f | anticipate seeing efficacy results later this year | 2026-04-26 | 2026-12-31 | Efficacy results from dose escalation studies for ABBV 619, an in vivo CD19 CAR T platform for autoimmune diseases. | Positive results could signal a transformative new approach to autoimmune diseases, offering deep and durable remission and a significant long-term growth driver. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_5d3fb65c | initiating a phase three study this year | 2026-04-26 | 2026-12-31 | Initiation of a Phase 3 study for tmAbA in an all-comers population in combination with bevacizumab for colorectal cancer. | This advances tmAbA into late-stage development for a multibillion-dollar opportunity in CRC, bolstering AbbVie's oncology pipeline. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_327b8be4 | data is expected around the middle of this year. | 2026-05-01 | 2026-06-30 | Phase 2 study data readout for ABBV 932 in bipolar depression. | Positive data could position ABBV 932 as a next-generation asset in psychiatry, potentially contributing to the replacement of Vraylar at its LOE in 2030. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_cba492a1 | an approval decision is expected this year. | 2026-04-26 | 2026-12-31 | US regulatory approval decision for Trenebody, a rapid-onset short-acting toxin for aesthetics. | Approval and subsequent launch could stimulate the aesthetics market by attracting new patients and ultimately accrue to Botox share, increasing overall revenue. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_80210779 | we will shortly see a readout over a head-to-head study with Entyvio. | 2026-04-26 | 2026-06-30 | Readout of head-to-head study data for SKYRIZI versus Entyvio in ulcerative colitis. | Positive data could provide a significant opportunity to continue SKYRIZI's momentum and leadership in the IBD market, differentiating it from other competitors. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| AMGN_17b91ee0 | study completion expected in 2026. | 2026-07-01 | 2026-12-31 | Completion of both Phase III studies for desodoliveb, a CD40 ligand targeting biotherapeutic, in Sjogren's disease. | Study completion is a critical step before data readout and potential regulatory filings, which could position desodoliveb as a significant treatment option in a challenging autoimmune condition. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| AMGN_1327efce | we expect study completion in the second half of this year. | 2026-07-01 | 2026-12-31 | Completion of Phase III studies for TestSpire in chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis. | Successful completion and subsequent positive data could lead to expanded indications for TestSpire, significantly increasing its market potential and revenue. | Ticker | 2026-02-03 | earnings_transcript | AMGN (ticker) |
| ABBV_800b4101 | an approval decision is anticipated in the third quarter for tevapadon in Parkinson's disease. | 2026-07-01 | 2026-09-30 | US commercial approval decision for tevapadon in Parkinson's disease. | Approval would add a new, potentially multibillion-dollar asset to AbbVie's neuroscience portfolio, offering a new treatment option for Parkinson's disease. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_47f622ef | data from both trials expected in the second half of this year. | 2026-07-01 | 2026-12-31 | Data readout from Phase 3 studies evaluating QLIPTA and UBRELVY for menstrual migraine prevention. | Positive data could lead to label expansions for these leading migraine products, addressing a distinct and difficult-to-treat subtype of migraine and further driving sales. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_ced91140 | by Q3 or so | 2026-07-01 | 2026-09-30 | Data from two additional cohorts of a Phase 2 study evaluating bradicilacin in major depressive disorder (MDD). | This data will inform the development strategy and Phase 3 plans, with bradicilacin having the potential to be a groundbreaking new treatment in depression due to its strong efficacy and short-acting profile. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |
| ABBV_c5da1469 | anticipated in the fourth quarter | 2026-10-01 | 2026-12-31 | US regulatory approval decision for RINVOQ in nonsegmental vitiligo. | Approval would expand RINVOQ's market to a new systemic indication, potentially adding to its multi-billion dollar sales trajectory. | Ticker | 2026-02-04 | earnings_transcript | ABBV (ticker) |